Halo Healthcare Inc. has signed a definitive license agreement with the University of North Dakota to develop biomarkers for the early detection of breast cancer.
The licensed UND technology is based on detecting cancer biomarkers in breast nipple aspirate fluid, which is the platform used for the Halo Breast Test marketed by Halo Healthcare for breast cancer risk assessment. More than 25,000 Halo tests have been performed worldwide, Irvine-based Halo said.
?This license has the opportunity of providing women all over the world an annual early breast detection test years before it is visible by mammography or other imaging technologies used for breast cancer screening,? Halo President and Chief Executive France Dixon Helfer said in a statement. ?Our scientists are developing a laboratory 'test kit' which could revolutionize the breast cancer care path.?
The company said its FDA-cleared Halo Breast Pap Test is the first fully automated noninvasive breast disease-screening device for use in physician offices. Like the Pap test for cervical cancer, Halo looks for cellular changes years before breast cancer is detectable by mammographic imaging.
The University of North Dakota, in Grand Forks, is the state?s most comprehensive intensive research university and the primary center for professional education and training. The university enrolled more than 14,000 students in fall 2011 in 220 fields of study.
Follow your favorites with My News
My News is a way to create a customized news feed based on companies and industries that matter to you.
kurt warner kurt warner missouri primary minnesota caucus knowshon moreno knowshon moreno sovereign citizen
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন